IDH1 and acute myeloid leukemia: In a phase 2 clinical trial in relapsed/refractory AML, single-agent venetoclax had an overall response rate of 19%, while 33% (4 out of 12) of patients with IDH1/2 mutations demonstrated CR87,88.